Background:
@EN Sparfloxacin, a new oral quinolone, has a broad spectrum, potent antimicrobial activity, prolonged half life, high concentration in sputum. The clinical efficacy and safety of sparfloxacin have been reported by some previous clinical studies
performed in Japan. The objectives of this study were to evaluate the clinical and antimicrobial efficacy of this drug in respiratory tract infections compared to those of enoxacin.
@ES Methods:
@EN We performed an open controlled, randomized study in 63 patients with acute bronchitis, pneumonia, and exacerbation of chronic bronchitis at Chung Nam University hospital and Dae Jeon St. Mary's hospital from October, 1994 to April, 1995. In
the
control group (n=32), 100 mg enoxacin was administered orally 3 times a day and in the test group (n=31), 200 mg sparfloxacin once a day.
@ES Results:
@EN The results were as follows;
1) There were no significant differences between the two groups in clinical efficacy, bacteriological finding, and usefulness.
2) Means and SD of MICs were 0.44 *0.89 */ml in the control group, 0.13*0.24 */ml in the test group. There was a significant difference in MICs between the two groups (P<0.05).
3) Headache, epigastric discomfort, and loss of appetite were observed in 7 cases of the control group and in 9 cases of the test group, and transient elevations of hepatic enzyme in 2 cases of the control group, and in 3 cases of the test group.
There was mild elevation of serum creatinime in 2 cases of the test group. Those laboratory abnormalities by therapy might be associated with their underlying diseases. There were no significant adverse effects caused by the drugs.
@ES Conclusion:
@EN In conclusion, sparfloxacin of 200 mg once a day was as effective and well tolerated as enoxacin of 100 mg three times per day in the treatment of respiratory tract infections. Sparfloxacin is more potent antibiotics because MICs of
sparfloxacin
were very lower than those of enoxacin.
|